EVOKE PHARMA, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-02: Form 8-K; Period of report 2013-12-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-12-02: Form 8-K; Period of report 2013-11-25; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2013-11-13: Form 8-K; Period of report 2013-11-13; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-10-08: Form 8-K; Period of report 2013-10-08; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-02 | 8-K | 2013-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 2, 2013, Evoke Pharma, Inc. (the “Company”) announced the appointment of Marilyn R. Carlson, D.M.D., M.D. as Chief Medical Officer, effective December 1, 2013. | d634013d8k.htm |
| 2013-12-02 | 8-K | 2013-11-25 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 25, 2013, Evoke Pharma, Inc. (the “Company”) entered into a Second Amendment to Master Services Agreement (the “Second Amendment”) with SynteractHCR, Inc. (“SynteractHCR”), amending the Master Agreement for Services by and between the Company and Synteract, Inc., dated January 30, 2009, as amended by Amendment No. 1 to Master Agreement for Services, dated January 30, 2011 (together with the Second Amendment, the “Services Agreement”). | d636070d8k.htm |
| 2013-11-13 | 8-K | 2013-11-13 | 2.02 Results of Operations and Financial Condition | 2.02 On November 13, 2013, Evoke Pharma, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2013. | d628485d8k.htm |
| 2013-10-08 | 8-K | 2013-10-08 | 8.01 Other Events | 8.01 On October 8, 2013, Evoke Pharma, Inc. (the “Company”) closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 315,000 shares of its common stock, at a price to the public of $12.00 per share, in connection with the Company’s recently announced underwritten initial public offering (the “Offering”). | d609854d8k.htm |
| 2013-09-30 | 8-K | 2013-09-30 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On September 30, 2013, in connection with the closing of the initial public offering of shares of its common stock (the “IPO”), Evoke Pharma, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Charter”) with the Secretary of State of the State of Delaware. | d604779d8k.htm |